Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal Qdenga Vaccine in Healthy Volunteers
NCT06837116Phase 1Completed
- Sponsor
- Prince of Songkla University
- Start
- Apr 2025
- Primary completion
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1 trial of dengue tetravalent vaccine, live, attenuated in dengue fever (2 arms), sponsored by Prince of Songkla University. Primary endpoints: Dengue IgG Level at Day 120, CD4 T Cell Responses at Day 120 and 1 more. Started Apr 2025; status: completed.
02
Drugs
dengue tetravalent vaccine, live, attenuated
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT06837116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06837116.